Clinical Trial

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Available
View on ClinicalTrials.gov →
Summary
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
Protocol Amendment History 5 changes
notable Trial sites expanded: 170 -> 210 locations 2026-08-11
notable Trial sites expanded: 154 -> 170 locations 2026-08-01
notable Trial sites expanded: 125 -> 154 locations 2026-07-25
notable Trial sites expanded: 73 -> 125 locations 2026-07-15
notable Trial sites expanded: 0 -> 73 locations 2026-07-09
Trial Details
NCT Number NCT07573215
Lead Sponsor Revolution Medicines, Inc.
Conditions PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Updated on ClinicalTrials.gov 2026-08-10